• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PER

PERCHERON THERAPEUTICS LIMITED

0.00% ! 0.9¢
Market Cap $9.786M  !
Healthcare Biotechnology
Add to My Watchlist

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a... Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PER
Ann: Quarterly Activities Report and Appendix 4C 		09:34 4 510
09:34 Last post  Motors Comments Created with Sketch.  4  Views Created with Sketch.  510 
PER
Ann: New Preclinical Data Reported for HMBD-002 		28/07/25 6 2.4K
28/07/25 Last post  Insulsa Comments Created with Sketch.  6  Views Created with Sketch.  2.4K 
PER
Ann: Topline Six-Month Results From Phase IIb Study of Avicursen
2 3 4
22/07/25 200 94K
22/07/25 Last post  Cuprum29 Comments Created with Sketch.  200  Views Created with Sketch.  94K 
PER
Ann: Percheron licenses HMBD-002 from Hummingbird Bioscience
2
21/07/25 69 21K
21/07/25 Last post  Motors Comments Created with Sketch.  69  Views Created with Sketch.  21K 
PER
Ann: Change of Director's Interest Notice - Dr James Garner 		03/07/25 11 4.9K
03/07/25 Last post  dazatoN Comments Created with Sketch.  11  Views Created with Sketch.  4.9K 
PER
Ann: Ceasing to be a substantial holder from PVL 		30/06/25 6 1.9K
30/06/25 Last post  Motors Comments Created with Sketch.  6  Views Created with Sketch.  1.9K 
PER
Ann: Percheron Therapeutics Limited Corporate Presentation 		27/06/25 10 2.5K
27/06/25 Last post  joe76 Comments Created with Sketch.  10  Views Created with Sketch.  2.5K 
PER
Ann: Trading Halt 		25/06/25 10 4.3K
25/06/25 Last post  Uboy Comments Created with Sketch.  10  Views Created with Sketch.  4.3K 

See All Discussions arrow Created with Sketch.

Timeline

Quarterly Activities Report and Appendix 4C
31 Jul 08:20
 
New Preclinical Data Reported for HMBD-002
23 Jul 08:46
 
Change of Director's Interest Notice - Dr James Garner
01 Jul 08:39
 
Ceasing to be a substantial holder from PVL
30 Jun 11:05
 
Percheron Therapeutics Limited Corporate Presentation
27 Jun 08:25
 
Percheron licenses HMBD-002 from Hummingbird Bioscience
26 Jun 10:18
 
View More arrow Created with Sketch.

Featured News

AII Analyst Buy Rating: Leading the Charge in Securing the Tungsten Supply Chain
right-arrow Created with Sketch.
NEWS Veteran executive to help turn Trigg into leading US-based antimony producer
right-arrow Created with Sketch.
NEWS Firetail scoops up untested land around Excelsior – including juicy mineralisation target
right-arrow Created with Sketch.
NEWS Friday's HotCopper trends: Renascor concentrate, Larvotto raise
right-arrow Created with Sketch.
NEWS Infini remobilising at Portland Creek after geo specialists line up 12 'priority' targets
right-arrow Created with Sketch.
NEWS 'Strong succession': WiseTech brings in old face to build new, post-White future
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
0.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $9.786M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
3 2287383 0.9¢
 

Sellers (Offers)

Price($) Vol. No.
1.0¢ 8818378 11
View Market Depth
Last trade - 09.29am 31/07/2025 (20 minute delay) ?
PER (ASX) Chart

Top Stories

Ionic Rare Earths falls -7% as momentum slips on vague production update

Ionic Rare Earths (ASX:IXR) @ a well-known and much-loved rare earths darling on something of a comeback run lately @ has slipped -7%, presumably as the market digests what a vague update released on Wednesday actually means. According to the company, @urgent supply requests from US, European and...
HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic Let’s check in with what HotCopper users are closely watching at lunchtime. Given that we’re basically on the deadline before companies get a scolding if they don’t report updates, on Wednesday, the ASX announcements list is basically one big wall o...
ASX Market Close: Index rebounds as investors buoyant | July 30, 2025 The ASX200 rebounded today and was in the green heading into the close. Investors were buoyant in response to positive inflation data that increased the odds of an interest rate cut in August.Staples, Real Estate and Discretionary were the strongest performing sectors. Utilities and IT were a dra...
ASX Market Open: Local bourse tipped to trade red after same on S&P500 The local market is tipped to trade red on Thursday following the S@P500 declining -0.12% overnight (though, the NASDAQ ended 30pts higher.) This comes even after the ASX200 re-entered record territory on Wednesday following a CPI read widely perceived as a signal the RBA is likely to cut in Augu...
Neurizon inks $1.5M loan against R&D Tax Rebate Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a non-dilutive loan agreement for $1.5 million to fund its current and future operations seeking to treat Huntington’s with its flagship drug NUZ-001.The funds in question are secured against it...

Featured News

NEWS Firetail scoops up untested land around Excelsior – including juicy mineralisation target
right-arrow Created with Sketch.
NEWS Friday's HotCopper trends: Renascor concentrate, Larvotto raise
right-arrow Created with Sketch.
NEWS Veteran executive to help turn Trigg into leading US-based antimony producer
right-arrow Created with Sketch.
NEWS 'Strong succession': WiseTech brings in old face to build new, post-White future
right-arrow Created with Sketch.
NEWS Mandalay Shareholders Overwhelmingly Approve Transaction with Alkane Resources
right-arrow Created with Sketch.
NEWS LISTEN NOW: HotCopperWire, our market watch podcast!
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.